123 related articles for article (PubMed ID: 8874970)
1. In vitro activity of cefetamet against enterobacteria expressing an SHV-5-type beta-lactamase.
Tzouvelekis LS; Prinarakis EE; Gazouli M; Miriagou V; Tzelepi E; Legakis NJ
Chemotherapy; 1996; 42(5):324-8. PubMed ID: 8874970
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel SHV beta-lactamase variant that resembles the SHV-5 enzyme.
Prinarakis EE; Tzelepi E; Gazouli M; Mentis AF; Tzouvelekis LS
FEMS Microbiol Lett; 1996 Jun; 139(2-3):229-34. PubMed ID: 8674992
[TBL] [Abstract][Full Text] [Related]
3. beta-Lactamase bioassay: a simplified method to determine extended-spectrum beta-lactamases (ESBL) in enterobacteria.
Silva-Sánchez J; Aguilar-Zacarías C
Arch Med Res; 1997; 28(2):285-7. PubMed ID: 9204623
[TBL] [Abstract][Full Text] [Related]
4. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.
Bedenić B; Beader N; Zagar Z
Clin Microbiol Infect; 2001 Nov; 7(11):626-35. PubMed ID: 11737087
[TBL] [Abstract][Full Text] [Related]
5. Interactions of ceftibuten with extended-spectrum beta-lactamases: a bacteriological and enzymatic analysis.
Thabaut A; Meyran M; Sofer L; Morand A; Labia R
Drugs Exp Clin Res; 1994; 20(2):49-54. PubMed ID: 7924896
[TBL] [Abstract][Full Text] [Related]
6. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum beta-lactamases conferring resistance to monobactams and oxyimino-cephalosporins in clinical isolates of Serratia marcescens.
Luzzaro F; Pagani L; Porta F; Romero E
J Chemother; 1995 Jun; 7(3):175-8. PubMed ID: 7562009
[TBL] [Abstract][Full Text] [Related]
8. Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens.
Speciale A; Caccamo F; Blandino G; Giacchi GT; Aleo G; Nicoletti G
Chemotherapy; 1996; 42(1):1-10. PubMed ID: 8751262
[TBL] [Abstract][Full Text] [Related]
9. [1st Spanish epidemic of plasmid resistance to 3d generation cephalosporins: the implication of SHV-2].
Fernández-Rodríguez A; Reguera JA; Pérez-Díaz JC; Picazo JJ; Baquero F
Enferm Infecc Microbiol Clin; 1992 Oct; 10(8):456-61. PubMed ID: 1489773
[TBL] [Abstract][Full Text] [Related]
10. Lytic activity of a new cephalosporin, cefuroxime, against gram-negative bacteria.
Russell AD; Tottle PC
Chemotherapy; 1978; 24(6):354-9. PubMed ID: 359269
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of meropenem and seven other beta-lactam antibiotics against K.pneumoniae and enterobacteriaceae producing beta-lactamases with extended spectrum].
Cavallo JD; Fabre R; Crenn Y; Meyran M
Pathol Biol (Paris); 1994 May; 42(5):365-8. PubMed ID: 7824297
[TBL] [Abstract][Full Text] [Related]
12. Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.
Thomson KS; Sanders CC; Moland ES
Antimicrob Agents Chemother; 1999 Jun; 43(6):1393-400. PubMed ID: 10348759
[TBL] [Abstract][Full Text] [Related]
13. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
Xiong Z; Zhu D; Zhang Y; Wang F
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins.
Jarlier V; Nicolas MH; Philippon A; Giroir AM; Grosset J
J Antimicrob Chemother; 1989 Aug; 24(2):165-72. PubMed ID: 2676939
[TBL] [Abstract][Full Text] [Related]
15. Serum bactericidal activity against Enterobacteriaceae producing broad-spectrum beta-lactamases in volunteers administered ofloxacin and cefotaxime, alone or combined.
Weber P; Boussougant Y; Farinotti R; Carbon C
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):524-6. PubMed ID: 2504593
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum beta-lactamases in clinical isolates of enterobacteria in Mexico.
Silva J; Aguilar C; Becerra Z; López-Antuñano F; García R
Microb Drug Resist; 1999; 5(3):189-93. PubMed ID: 10566868
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).
Neu HC; Chin NX; Labthavikul P
Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of a new plasmid-encoded SHV-type beta-lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae.
Podbielski A; Schönling J; Melzer B; Warnatz K; Leusch HG
J Gen Microbiol; 1991 Mar; 137(3):569-78. PubMed ID: 2033379
[TBL] [Abstract][Full Text] [Related]
19. [Effect of inoculum size on sensitivity and specificity of the double-disk synergy test for the detection of wide-spectrum beta-lactamases].
Bedenić B; Boras A
Lijec Vjesn; 2001; 123(11-12):293-6. PubMed ID: 11930754
[TBL] [Abstract][Full Text] [Related]
20. Third generation oral cephalosporins: comparative in vitro kinetics.
Speciale A; Blandino G; Nicoletti G
J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
